obstructive hypertrophic cardiomyopathy
Cardiovascular · 2022–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mavacamten Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), specifically NYHA class II-III with peak LVOT gradient ≥30 mmHg. | Jul 2023 | Not recommended | 5 individuals Cardiomyopathy Association of Australia |
| mavacamten Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) with peak LVOT gradient ≥50 mm Hg who remain symptomatic despite prior… | Nov 2023 | Recommended with restriction | input received |
| mavacamten Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The drug is indicated for patients with NYHA class II-III symptoms,… | Nov 2022 | Not recommended | input received |
Who spoke
Cardiomyopathy Association of Australia
What the PBS pays
$16M in government benefit over 2024–25, across 7,007 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| mavacamten | $16.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| mavacamtenMavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | recommended restricted | 2023-09 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.